Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that the Independent Data Safety Monitoring Board (DSMB) has reviewed the preliminary data from its Phase 2b/3 Alzheimer’s study of ANAVEX®2-73 (blarcamesine). The DSMB recommended continuing the study without modifications. The ongoing clinical trial is over 92% enrolled, focusing on safety and efficacy, with endpoints assessing cognition and daily function. ANAVEX®2-73 targets the sigma-1 receptor and may restore neural homeostasis, signaling potential in neurodegenerative treatments.
Anavex Life Sciences Corp. (AVXL) announced the inclusion of ANAVEX®2-73 (blarcamesine) in a peer-reviewed article published in Neuropharmacology. This publication highlights the drug's potential in treating Alzheimer's disease based on a 57-week Phase 2a trial with 32 patients, showing significant improvements in cognition and daily activities, particularly in those with a functional SIGMAR1 gene. A follow-up study demonstrated further efficacy. An ongoing Phase 2b/3 trial is set to refine patient selection using these findings.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that Christopher U. Missling, PhD, President and CEO, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available as a webcast on Anavex's website starting March 9, 2021. The company is focused on developing therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. Anavex’s lead drug candidate, ANAVEX®2-73, has shown promising results in clinical trials for Alzheimer's and Parkinson’s diseases, targeting key receptors to restore cellular homeostasis.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that its CEO, Christopher U. Missling, PhD, will participate in the NIH virtual Rare Disease Day® event on March 1, 2021. The event aims to raise awareness about rare diseases and facilitate discussions among stakeholders in research and therapeutic development. Anavex is committed to advancing therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s. This event is free and open to the public, showcasing discussions, stories, and collaborations in the field.
Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, announced that CEO Christopher U. Missling will present at the Precision in Clinical Trials Virtual Summit on February 24, 2021. The company focuses on therapeutics for neurodegenerative disorders, with lead candidate ANAVEX®2-73 having successfully completed Phase 2a trials for Alzheimer's and Parkinson's diseases. The candidate targets sigma-1 and muscarinic receptors and has shown potential in halting disease progression according to preclinical studies.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Christopher U. Missling, PhD, President and CEO, will present on February 25th, 2021, at 12:00 p.m. EST, discussing the company's progress on therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s. The presentation will be available via webcast and can be replayed online. Anavex is known for its lead drug candidate, ANAVEX®2-73, which recently completed successful clinical trials.
Anavex Life Sciences Corp. (Nasdaq: AVXL) reported its financial results for the fiscal quarter ended December 31, 2020, posting a net loss of $7.9 million, or $0.12 per share. As of the reporting date, the company had approximately $75 million in cash and cash equivalents, providing a runway for up to three years. ANAVEX®2-73 is advancing in clinical trials for Alzheimer’s, Parkinson’s, and Rett syndrome, with 86% recruitment in the ongoing Phase 2b/3 Alzheimer's trial. Recent milestones include a $995,862 research grant from the Michael J. Fox Foundation.
Anavex Life Sciences Corp. (Nasdaq: AVXL) will release its financial results for the fiscal quarter ending December 31, 2020, on February 11, 2021. A conference call will be held at 4:30 pm ET to discuss these results, along with updates on clinical programs and corporate highlights. Anavex is focused on developing therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. The company’s lead candidate, ANAVEX®2-73, has shown promise in clinical trials targeting significant CNS diseases.
Anavex Life Sciences Corp. (Nasdaq: AVXL) has received a research grant of $995,862.51 from The Michael J. Fox Foundation for Parkinson’s Research to further develop ANAVEX®2-73 (blarcamesine) as a treatment for Parkinson’s disease. This funding follows a previous award that supported preclinical studies indicating the drug’s potential as a disease-modifying treatment. ANAVEX®2-73 targets the sigma-1 receptor, crucial for promoting neuroplasticity and restoring neural cell homeostasis. Parkinson's disease affects over 10 million people globally, underlining the significance of this research.
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that Christopher U. Missling, PhD, will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. This clinical-stage biopharmaceutical company focuses on developing innovative therapies for neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Anavex's lead drug candidate, ANAVEX®2-73, has shown promise in recent clinical trials, demonstrating its ability to restore cellular balance and potentially reverse Alzheimer’s disease progression. A webcast of the presentation will be available on Anavex’s website.